Aravive Biologics
Financials
Estimates*
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.4m | 4.8m | 5.7m | 7.4m | 9.1m | 5.5m | 2.0m |
| % growth | (97 %) | 247 % | 20 % | 31 % | 23 % | (40 %) | (64 %) |
| EBITDA | (72.8m) | (18.2m) | (19.2m) | (40.6m) | (70.8m) | - | - |
| % EBITDA margin | (5313 %) | (383 %) | (338 %) | (546 %) | (775 %) | - | - |
| Profit | (76.3m) | (18.2m) | (30.5m) | (39.2m) | (76.3m) | - | - |
| % profit margin | (5568 %) | (383 %) | (537 %) | (526 %) | (835 %) | - | - |
| R&D budget | 11.1m | 12.8m | 17.6m | 37.5m | 66.9m | - | - |
| R&D % of revenue | 808 % | 270 % | 310 % | 504 % | 733 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - |
| N/A | - |
| N/A | N/A | IPO | |
$20.0m | Grant | ||
$2.6m | Grant | ||
| N/A | $21.0m | Post IPO Equity | |
$10.0m | Post IPO Equity | ||
* | $41.5m | Private Placement VC | |
| Total Funding | CAD87.4m | ||
Related Content
Recent News about Aravive Biologics
EditAravive, Inc. is a biopharmaceutical company focused on developing innovative treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company's lead product candidate, AVB-500, targets the GAS6-AXL signaling pathway, a crucial driver of cell migration and invasion in diseases. Aravive's primary clinical focus is on recurrent platinum-resistant ovarian cancer, a condition often diagnosed at an advanced stage when metastasis has already occurred.
Aravive operates in the biotechnology and pharmaceutical markets, primarily serving patients suffering from severe and advanced diseases. The company's business model revolves around the research, development, and commercialization of novel therapeutic agents. Revenue generation is expected to come from the successful development and subsequent commercialization of its drug candidates, either through direct sales or partnerships with larger pharmaceutical companies.
Aravive's approach leverages cutting-edge scientific insights into the mechanisms of disease progression, aiming to provide effective and targeted treatments that can significantly improve patient outcomes.
Keywords: biopharmaceutical, AVB-500, GAS6-AXL, ovarian cancer, fibrosis, cell migration, disease progression, therapeutic agents, biotechnology, pharmaceutical.
